Apyx Medical Corp
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
APYX$2.93-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
(In thousands, except share and per share data)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $31,740 | $31,741 |
| Trade accounts receivable, net of allowance of $1,020 and $1,000 | 16,776 | 15,480 |
| Inventories, net of provision for obsolescence of $1,207 and $1,032 | 8,602 | 7,564 |
| Prepaid expenses and other current assets | 1,353 | 1,655 |
| Total current assets | 58,471 | 56,440 |
| Property and equipment, net | 2,371 | 1,987 |
| Operating lease right-of-use assets | 4,218 | 4,703 |
| Finance lease right-of-use assets | 28 | 48 |
| Other assets | 1,752 | 1,664 |
| Total assets | $66,840 | $64,842 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,058 | $2,615 |
| Accrued expenses and other current liabilities | 8,214 | 7,751 |
| Current portion of operating lease liabilities | 407 | 335 |
| Current portion of finance lease liabilities | 21 | 20 |
| Total current liabilities | 11,700 | 10,721 |
| Long-term debt, net of debt discounts and issuance costs | 34,849 | 33,893 |
| Long-term operating lease liabilities | 4,051 | 4,483 |
| Long-term finance lease liabilities | 12 | 33 |
| Long-term contract liabilities | 1,050 | 1,118 |
| Other liabilities | 347 | 259 |
| Total liabilities | 52,009 | 50,507 |
| Commitments and Contingencies (Note 17) | ||
| EQUITY | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 75,000,000 shares authorized; 41,785,946 issued and outstanding as of December 31, 2025, and 37,793,886 issued and outstanding as of December 31, 2024 | 42 | 38 |
| Additional paid-in capital | 103,620 | 92,083 |
| Accumulated deficit | (89,122) | (77,911) |
| Total stockholders’ equity | 14,540 | 14,210 |
| Non-controlling interest | 291 | 125 |
| Total equity | 14,831 | 14,335 |
| Total liabilities and equity | $66,840 | $64,842 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.